VectorBuilder’s Chief Scientist Dr. Bruce Lahn Named to Forbes China’s Top 100 Most Influential Chinese
Chicago, IL – November 14, 2024 — VectorBuilder, a global leader in gene delivery solutions, proudly announces that its chief scientist, Dr. Bruce Lahn, has been recognized on the 2024 Forbes China 100 Most Influential Chinese list. This distinguished annual selection honors 100 prominent Chinese figures shaping business, culture, and philanthropy globally, with past recipients including NVIDIA’s Jenson Huang. Dr. Lahn was chosen for his pivotal contributions to advancing life sciences worldwide.
Dr. Lahn’s impressive career in genetics spans over 30 years. A Harvard alum with a Ph.D. from MIT, he has held a tenured professorship at the University of Chicago and conducted influential research at the Howard Hughes Medical Institute. With over 100 published works in international journals, his research has garnered numerous accolades, including the 2023 Forbes China Globalization Innovators Selection Top 30 Individuals and the 2024 PharmaVoice 100 recognition.
In 2014, Dr. Lahn’s entrepreneurial drive led him to launch VectorBuilder, an online platform that has revolutionized gene delivery. By automating and simplifying the design and ordering of gene delivery vectors, VectorBuilder has streamlined research for hundreds of thousands of life science labs around the world. The platform’s innovation and impact are reflected in over 5,000 scientific publications, and VectorBuilder’s client base spans more than 4,500 institutions in 90+ countries, including 90% of the top 100 QS-ranked universities and 90% of the top 30 global pharmaceutical companies.
Further cementing his legacy in the field, Dr. Lahn established the world’s first Gene Delivery Research Institute in Guangzhou in late 2023. The institute is dedicated to pioneering gene delivery research and addressing technological barriers in the field, bridging basic research with real-world therapeutic applications. In July 2024, VectorBuilder was crucial in securing Orphan Drug Designation (ODD) from the U.S. FDA for Lantu Biopharma’s promising gene therapy drug, LTGT06.
Reflecting on the honor, Dr. Lahn commented, “This recognition is a testament to the dedication of the entire VectorBuilder team. We remain committed to advancing scientific innovation globally and collaborating with leading researchers to improve human health.”
Under Dr. Lahn’s visionary leadership, VectorBuilder has expanded its footprint globally, establishing subsidiaries and offices across North America, Europe, and Japan. With a commitment to delivering high-quality gene delivery solutions and fostering international collaboration, VectorBuilder has solidified its position as a leader in the life sciences industry.
About VectorBuilder Inc.
VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Design Studio is a transformative innovation that allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions that include advanced AAV capsid engineering capabilities and state-of-the-art GMP facilities. With leading R&D and CDMO manufacturing capacity, the VectorBuilder team strives to provide the most effective gene delivery solutions and develop new tools for life sciences research and genetic medicine.
To learn more about VectorBuilder, visit www.vectorbuilder.com
